Brief: EMA's CHMP Starts Review Of Tecovirimat SIGA
25/07/2025 11:53
July 25 (Reuters) - EMA's CHMP: EMA'S CHMP-STARTED REVIEW OF TECOVIRIMAT SIGA TO CONSIDER EMERGING DATA FROM RECENT CLINICAL TRIALS SUGGESTING LACK OF EFFECTIVENESS IN MPOX TREATMENT Further company coverage: SIGA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on SIGA Technologies
See all newsBrief: Siga Secures Contract Valued At Up To $15 Million From Canadian Department Of National Defence To Purchase Tpoxx®
SIGA Technologies Q2 revenue, profit drop as contract ends
SIGA Technologies Q1 revenue falls, net loss widens
Brief: SIGA Technologies Q1 EPS USD -0.05
Brief: EMA Recommends Restricting Use Of Tecovirimat SIGA